Protara Therapeutics, Inc. announced that effective October 15, 2021, Mart?n Sebastian Olivo, M.D. will no longer be employed by the Company as Chief Medical Officer. Dr. Olivo and the Company have entered into a consulting agreement, effective October 16, 2021, pursuant to which Dr. Olivo will provide consulting and transition services to the Company through November 22, 2021 and the Company promoted Jathin Bandari, M.D. to the position of VP, Head of Clinical Development and Interim Chief Medical Officer. Dr. Bandari joined the company in April 2020. He is a Urologic Oncologist who specializes in both minimally invasive urologic oncology and advanced open pelvic and retroperitoneal cancer surgery.